The European Medicines Agency and EUnetHTA, the European network for Health Technology Assessment (HTA), met to review the progress of their cooperation in London on May 14, it was reported today (June 7). This was the sixth meeting since the start of their collaboration in 2010.
The focus of this meeting was on how regulators and HTA bodies can work together to facilitate drug development by cooperating in giving advice to pharmaceutical companies. EUnetHTA is piloting joint early dialogue with technology sponsors by a number of national HTA agencies and the EMA has a scientific advice program in place to guide companies in the design of trials that will generate appropriate evidence to enable better decision-making by all players in the health care systems of European Union member states.
Cooperation has significance for patients
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze